Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(Rs.in Million, except per share data)

		PARTICULARS	STANDALONE						CONSOLIDATED					
			QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
			30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1		Revenue from operations	2,445.83	2,224.86	2,440.42	4,670.68	4,354.80	8,379.18	4,914.65	5,198.79	4,502.65	10,113.44	8,579.86	17,233.08
2		Other income	45.36	14.02	101.94	50.18	138.82	349.51	49.56	13.40	42.62	27.03	108.89	287.92
3		Total Income	2,491.19	2,238.88	2,542.36	4,720.86	4,493.62	8,728.69	4,964.21	5,212.19	4,545.27	10,140.47	8,688.75	17,521.00
4		Expenses												
		Cost of materials consumed	1,634.44	1,455.98	1,144.01	3,090.42	2,134.62	4,018.22	2,641.98	3,123.48	2,090.23	5,765.46	4,348.77	8,232.70
		Purchase of stock in trade	37.49	14.88	3.71	52.38	8.42	36.91	293.16	58.20	352.63	351.36	551.58	886.01
		Changes in inventories of finished goods/WIP/stock in trade	10.56	(141.35)	193.65	(130.79)	223.15	404.05	21.77	(124.85)	(31.80)	(103.08)	(232.44)	105.75
		Employee benefits expense	204.22	202.78	193.56	407.00	379.76	759.80	722.66	734.29	594.69	1,456.95	1,162.11	2,439.01
		Finance costs	154.87	133.82	187.29	288.69	300.73	669.87	205.92	140.05	178.48	345.97	327.04	729.40
		Depreciation and amortisation expense	137.92	135.12	134.74	273.04	268.77	536.77	199.19	191.56	176.55	390.75	337.88	709.19
		Other expenses	623.43	624.37	723.49	1,238.60	1,380.03	2,681.31	1,212.75	1,314.92	1,140.62	2,491.75	2,190.63	4,500.82
		Total Expenses	2,802.93	2,425.60	2,580.46	5,219.34	4,695.48	9,106.92	5,297.43	5,437.65	4,501.40	10,699.16	8,685.57	17,602.88
5		Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)	(311.74)	(186.72)	(38.10)	(498.48)	(201.86)	(378.23)	(333.22)	(225.46)	43.87	(558.69)	3.18	(81.88)
6		Exceptional items (Refer Note 5)	-	-	-	-	-	162.70	19.26	111.10	-	130.36	-	254.60
7		Profit / (Loss) before share of profit / (loss) of associate (5-6)	(311.74)	(186.72)	(38.10)	(498.48)	(201.86)	(540.92)	(352.48)	(336.56)	43.87	(689.05)	3.18	(336.48)
8		Share of profit / (loss) of associate	-	-	-	-	-	-	3.61	13.97	(3.58)	17.58	5.33	16.62
9		Profit / (Loss) before tax from continuing operations (7-8)	(311.74)	(186.72)	(38.10)	(498.48)	(201.86)	(540.92)	(348.87)	(322.59)	40.29	(671.47)	8.51	(319.86)
10		Tax Expenses												
		- Current tax	-	-	-	-	-	-	44.89	38.57	56.11	83.46	115.87	179.21
		- Deferred tax	(111.65)	(63.60)	(1.71)	(175.24)	(58.67)	(211.26)	(112.95)	(43.20)	2.84	(156.14)	(57.17)	(183.76)
		Total Tax Expenses	(111.65)	(63.60)	(1.71)	(175.24)	(58.67)	(211.26)	(68.06)	(4.63)	58.95	(72.68)	58.70	(4.55)
11		Profit / (Loss) from continuing operations for the period (9-10)	(200.09)	(123.12)	(36.39)	(323.24)	(143.19)	(329.66)	(280.81)	(317.96)	(18.66)	(598.79)	(50.19)	(315.31)
12		Discontinued operations (Refer Note 6)												
		Profit / (Loss) from discontinued operation before tax	-	-		-	-	-	(16.19)	(18.26)	(130.84)	(34.45)	(205.80)	552.42
		Tax expense of discontinued operations	-	-		-	-	-	-	-	-	-	0.32	1.68
		Profit / (Loss) from discontinued operations	-	-	-	-	-	-	(16.19)	(18.26)	(130.84)	(34.45)	(206.12)	550.74
13		Profit / (Loss) for the period (11+12)	(200.09)	(123.12)	(36.39)	(323.24)	(143.19)	(329.66)	(297.00)	(336.22)	(149.50)	(633.24)	(256.31)	235.43
14		Other comprehensive income												
A		Items that will not be reclassified to profit or loss												
	(i)	Remeasurements of defined benefit plans	2.31	(0.70)	(11.67)	1.61	(10.11)	(1.61)	2.31	(0.70)	(11.67)	1.61	(10.11)	(1.24)
	(ii)	Income tax relating to Items that will not be reclassified to profit or loss	(0.81)	0.24	4.08	(0.56)	3.53	0.56	(0.81)	0.24	4.08	(0.56)	3.53	0.56
B		Items that will be reclassified to profit or loss												
	(i)	Exchange differences on translating the financial statements of foreign operations							(65.16)	135.76	32.75	70.60	149.79	80.96
	(ii)	The effective portion of gain or loss on hedging instruments in a cash flow hedge	21.54	57.33	(53.71)	78.88	(51.81)	(70.57)	21.54	57.33	(53.71)	78.88	(51.81)	(70.57)
	(iii)	Income tax relating to Items that will be reclassified to profit or loss	(7.53)	(20.03)	18.77	(27.56)	18.10	24.66	(7.53)	(20.03)	18.77	(27.56)	18.10	24.66
		Other comprehensive income	15.51	36.84	(42.53)	52.37	(40.29)	(46.96)	(49.65)	172.60	(9.78)	122.97	109.50	34.37
15		Total comprehensive income for the period (13+14)	(184.58)	(86.28)	(78.92)	(270.87)	(183.48)	(376.62)	(346.65)	(163.62)	(159.28)	(510.27)	(146.81)	269.80

ANNEXURE - 1

Camlin Fine Sciences

MUKESH M. ALYANIWALLA & MISTRY LLP

CAMLIN FINE SCIENCES LIMITED MUMBAI

		PARTICULARS	STANDALONE						CONSOLIDATED					
			QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
			30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
16		Profit / (Loss) attributable to:												
	(i)	Owners of the Company							(278.54)	(317.06)	(143.84)	(595.62)	(243.45)	276.27
	(ii)	Non-controlling interests							(18.46)	(19.16)	(5.66)	(37.62)	(12.86)	(40.84)
		Profit attributable to owners arises from:												
		Continuing operations							(267.35)	(309.02)	(17.14)	(576.39)	(46.72)	(300.81)
		Discontinued operations							(11.19)	(8.04)	(126.70)	(19.23)	(196.73)	577.08
17		Other comprehensive income attributable to:												
	(i)	Owners of the Company							(39.76)	177.48	(1.15)	137.74	117.91	71.11
	(ii)	Non-controlling interests							(9.89)	(4.88)	(8.63)	(14.77)	(8.41)	(36.74)
18		Total comprehensive income attributable to:												
	(i)	Owners of the Company							(318.30)	(139.58)	(144.99)	(457.88)	(125.54)	347.38
	(ii)	Non-controlling interests							(28.35)	(24.04)	(14.29)	(52.39)	(21.28)	(77.58)
		Total comprehensive income attributable to owners arises												
		Continuing operations							(307.11)	(131.54)	(18.29)	(438.65)	71.20	(229.70)
		Discontinued operations							(11.19)	(8.04)	(126.70)	(19.23)	(196.73)	577.08
19		Paid-up Equity Share Capital (Face Value Rs.1/- per share)	192.10	192.10	187.98	192.10	187.98	192.09	192.10	192.10	187.98	192.10	187.98	192.09
20		Other Equity				8,847.42	8,255.77	9,096.16				9,528.63	8,707.75	10,216.71
		Earnings per Share (EPS) for profit from continuing operation (of Re 1/-each) (not annualised)												
		Basic (Rs.)							(1.39)	(1.60)	(0.09)	(3.00)	(0.25)	(1.59)
		Diluted (Rs.)							(1.39)	(1.60)	(0.09)	(3.00)	(0.25)	(1.59)
		Earnings per Share (EPS) for profit from discontinued operation (of Re 1/-each) (not annualised)												
		Basic (Rs.)							(0.06)	(0.05)	(0.67)	(0.10)	(1.05)	3.05
		Diluted (Rs.)							(0.06)	(0.05)	(0.67)	(0.10)	(1.05)	3.01
21		Earnings per Share (EPS) for profit from continuing and discontinued operation (of Re 1/-each) (not annualised)												
		Basic (Rs.)	(1.04)	(0.64)	(0.19)	(1.68)	(0.76)	(1.74)	(1.45)	(1.65)	(0.77)	(3.10)	(1.30)	1.46
		Diluted (Rs.)	(1.04)	(0.64)	(0.19)	(1.68)	(0.76)	(1.74)	(1.45)	(1.65)	(0.77)	(3.10)	(1.30)	1.44

Notes to Standalone and Consolidated Unaudited Financial Results:

1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 03, 2026. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India.

2 Other income / Other expense above relating to continuing operations includes net foreign exchange gain / (loss) for each reporting period as under:

(Rs.in Million)

Particulars	STANDALONE						CONSOLIDATED					
	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Exchange gain	31.94	-	74.48	22.74	80.59	239.92	35.93	-	28.68	-	90.12	189.51
Exchange loss	-	9.20	-	-	-	-	-	83.69	-	47.76	-	-
Total Exchange Gain / (Loss)	31.94	(9.20)	74.48	22.74	80.59	239.92	35.93	(83.69)	28.68	(47.76)	90.12	189.51

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098
CIN: L74100MH1993PLC075361
+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED MUMBAI

CFS Camlin Fine Sciences

3 Finance costs of continuing operation include foreign exchange gain / (loss) for each reporting period as under:

(Rs.in Million)

Particulars	STANDALONE						CONSOLIDATED					
	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Exchange gain	-	1.83	-	-	-	-	-	22.73	-	-	-	-
Exchange loss	24.15	-	66.65	22.32	65.62	174.27	37.21	-	37.03	14.49	46.28	82.39
Total Exchange Gain / (Loss)	(24.15)	1.83	(66.65)	(22.32)	(65.62)	(174.27)	(37.21)	22.73	(37.03)	(14.49)	(46.28)	(82.39)

4 During the current quarter, the Company has neither issued nor allotted employee stock options under any of the Employees Stock Option Plans (ESOP) . 39,000 employee stock options have lapsed under ESOP-2021 which have been added back to the option pool and are eligible for re-issue.

5 On June 23, 2026, the Company launched an open offer to acquire up to 738,099 equity shares held by minority shareholders of Vinpai S.A. ("Vinpai") at a price of Euro 3.60 per share (face value of Euro 0.10 per share and securities premium of Euro 3.50 per share). The open offer closed on July 6, 2026, pursuant to which 501,842 equity shares were tendered and acquired for consideration of INR 200.90 million. Consequently, the Company's shareholding in Vinpai increased to 4,325,158 equity shares (excluding 26,736 treasury shares), representing 94.82% of Vinpai share capital.
In accordance with Ind AS 110, the acquisition of the additional equity interest has been accounted for as an equity transaction and hence the consideration paid and the negative carrying value of the net assets attributable to the acquired non-controlling interest of INR 49.75 million, amounting to INR 250.65 million has been recognized in Other Equity.
Further, the Company incurred expenses of INR 19.26 million relating to the open offer has been disclosed under exceptional item.

6 Loss from 'Discontinued Operations -Expenditure of Rs. 16.19 Million relating to the discontinued operations of subsidiary, CFS Wanglong Flavours (Ningbo) Co. Ltd.

7 During the current quarter, Company has incurred expenses of INR 50.64 million in respect of the Diphenol plant at Dahej. The plant remained under shutdown during the quarter owing to prevailing geopolitical uncertainties and adverse economic conditions.

8 As per the requirements of Ind AS-108 on "Operating Segment", Consolidated segment wise information has been provided in Annexure -1.

For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

Place: Mumbai
Date: November 03, 2026

KALYANIWALLA & MISTRY LLP

CAMLIN FINE SCIENCES LIMITED MUMBAI

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000
+91 22 2832 4404
corporate@camlinfs.com
www.camlinfs.com

Camlin Fine Sciences

CFS® Camlin Fine Sciences

CAMLIN FINE SCIENCES LIMITED
BALANCE SHEET AS AT SEPTEMBER 30, 2026

(Rs.in Million)

			PARTICULARS	STANDALONE		CONSOLIDATED	
				30.09.2026 (Unaudited)	31.03.2026 (Audited)	30.09.2026 (Unaudited)	31.03.2026 (Audited)
			ASSETS				
(1)			Non-Current Assets				
	(a)		Property, Plant and Equipment	4,790.94	4,876.15	5,711.22	5,692.11
	(b)		Capital work-in-progress	114.92	226.97	237.02	328.52
	(c)		Right-Of-Use Assets	271.70	263.64	615.64	558.78
	(d)		Investment Property	-	-	-	-
	(e)		Goodwill	-	-	2,334.11	2,334.11
	(f)		Intangible Assets	102.92	115.97	265.18	288.74
	(g)		Financial Assets				
		(i)	Investments	2,398.45	2,170.90	310.10	302.62
		(ii)	Other financial assets	51.67	59.14	187.77	183.54
	(h)		Deferred tax assets (net)	805.93	658.81	1,001.59	873.84
	(i)		Income tax assets	75.63	73.98	188.91	251.62
	(j)		Other non-current assets	46.56	58.95	49.85	60.24
			Total Non-current Assets	8,658.72	8,504.50	10,901.39	10,874.12
(2)			Current Assets				
	(a)		Inventories	2,951.62	2,435.08	5,805.36	5,037.42
	(b)		Financial assets				
		(i)	Investments	-	-	-	-
		(ii)	Trade receivables	4,567.24	4,740.96	3,371.68	3,730.16
		(iii)	Cash and cash equivalents	1.64	362.19	494.97	1,085.55
		(iv)	Other bank balances	191.76	446.69	191.76	446.69
		(v)	Loans	558.90	551.72	-	-
		(vi)	Other financial assets	424.55	363.00	340.70	578.29
	(c)		Other current assets	290.12	293.09	1,549.17	1,465.19
			Total Current Assets	8,985.83	9,192.73	11,753.64	12,343.30
	(d)		Asset held for sale	21.61	21.61	21.61	21.61
			TOTAL ASSETS	17,666.16	17,718.84	22,676.64	23,239.03
			EQUITY AND LIABILITIES				
(1)			EQUITY				
	(a)		Equity Share Capital	192.10	192.09	192.10	192.09
	(b)		Other Equity	8,847.42	9,096.16	9,528.63	10,216.71
	(c)		Non-Controlling Interest	-	-	(407.17)	(400.74)
			Total Equity	9,039.52	9,288.25	9,313.56	10,008.07
			LIABILITIES				
(2)			Non-current Liabilities				
	(a)		Financial Liabilities				
		(i)	Borrowings	1,863.02	2,103.85	2,653.63	3,026.06
		(ii)	Lease liabilities	52.57	40.39	418.66	344.02
		(iii)	Other financial liabilities	-	-	3.78	3.22
	(b)		Provisions	75.04	72.75	75.04	72.75
	(c)		Deferred tax liabilities (net)	-	-	39.05	39.08
	(d)		Other non-current liabilities	-	-	1.47	1.62
			Total Non-Current Liabilities	1,990.63	2,217.00	3,191.63	3,486.74
(3)			Current Liabilities				
	(a)		Financial Liabilities				
		(i)	Borrowings	2,501.52	2,613.96	3,639.99	3,654.75
		(ii)	Lease liabilities	51.15	60.79	169.54	176.10
		(iii)	Trade Payables				
			(A) Total outstanding dues of micro enterprises and small enterprises; and	1,079.00	834.17	1,079.27	836.08
			(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	2,657.26	2,322.33	4,381.55	4,215.85
		(iv)	Other financial liabilities	256.20	253.17	592.15	617.76
	(b)		Other current liabilities	41.93	82.14	222.14	151.88
	(c)		Provisions	48.95	47.03	85.68	91.04
	(d)		Current tax liabilities (net)	-	-	1.13	0.76
			Total Current Liabilities	6,636.01	6,213.59	10,171.45	9,744.22
			Total Liabilities	8,626.64	8,430.59	13,363.08	13,230.96
			TOTAL EQUITY AND LIABILITIES	17,666.16	17,718.84	22,676.64	23,239.03

KANIWALLA & MISTRY

Place: Mumbai
Date: November 03, 2026

For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

CAMLIN FINE SCIENCES LIMITED MUMBAI

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED
STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

Rs. (in Millions)

Particulars	For half year ended September 30,2026 (Unaudited)	For half year ended September 30,2025 (Unaudited)
Cash Flow from Operating Activities		
(Loss) Before Tax	(498.48)	(201.87)
Adjustment for:		
Depreciation and Amortisation Expense	273.04	268.77
Finance Costs	288.69	300.73
Foreign Exchange Loss / (Gain) (Unrealised)	(16.44)	(66.21)
(Gain)/ Loss on sale of Property, Plant & Equipment and Intangible Assets	2.46	0.93
Allowance/ (Reversal) of Credit Loss	30.59	(0.76)
Expense/(Reversal) recognised in respect of equity-settled share-based payments	14.95	-
Provision for Defined Benefit Plans	5.81	18.37
Interest Income	(24.61)	(37.39)
Interest Income on other financial assets	(0.85)	(0.37)
Guarantee Commission	(1.37)	(1.37)
Provision for interest on MSME	33.51	12.26
Net Gain arising on Financial Assets measured at Fair Value Through Profit or Loss (FVTPL)	-	(18.07)
Operating Profit before working capital changes	107.30	275.02
Adjustment for:		
Increase/(Decrease) in Non Financial Liabilities	(41.82)	(21.08)
Increase/(Decrease) in Financial Liabilities	662.89	59.15
(Increase)/Decrease in Non Financial Assets	(512.52)	225.64
(Increase)/Decrease in Financial Assets	110.03	(107.48)
Cash generated from operations	325.88	431.25
Taxes Paid (Net)	(1.67)	(1.17)
Net Cash Flow from Operating activities	324.21	430.08
Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment and Intangible Assets	(40.69)	(118.42)
Sale of Property, Plant & Equipment and Intangible Assets	(0.02)	-
Acquisition of subsidiary	67.60	(34.50)
Loan to Subsidiary and others	(1.88)	(15.18)
Maturity of / (Investment in) Fixed Deposit	(24.25)	165.48
Interest Received	2.83	8.82
Net Cash Flow used in Investing Activities	3.60	6.20
Cash Flow from Financing Activities		
Proceeds from Issue of Equity Shares under Right issue and Employee Stock Option Plan	0.10	4.53
Proceeds from / (Repayment of) Long Term Borrowings (Net)	(336.10)	223.71
Proceeds from / (Repayment of) Short Term Borrowings (Net)	(37.97)	(646.67)
Payment of lease liabilities	(41.90)	(37.73)
Interest Paid	(272.49)	(219.96)
Net Cash Flow from/ (used in) Financing Activities	(688.36)	(676.12)
Net Increase in Cash & Cash Equivalents	(360.55)	(239.84)
Cash & Cash Equivalents at the beginning of the year	362.19	360.66
Cash & Cash Equivalents at the end of period	1.64	120.82

Note :
(a) The above Cash Flow Statement has been prepared under the "Indirect Method as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

(b) Cash and Cash Equivalents comprises of :

Particulars	For half year ended September 30,2026 (Unaudited)	For half year ended September 30,2025 (Unaudited)
Balances with Banks in Current Accounts	1.08	5.77
Bank deposits with original maturity of less than three months	-	114.73
Cash on Hand	0.56	0.32
Cash and cash equivalents in Standalone Balance Sheet	1.64	120.82

For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

CAMLIN FINE SCIENCES LIMITED MUMBAI

Place: Mumbai
Date: November 03, 2026

KALYANIWALLA & MISTRY LLP

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026

(Rs.in Million)

Particulars	For the half year ended September 30, 2026 (Unaudited)	For the half year ended September 30, 2025 (Unaudited)
Cash Flow from Operating Activities		
Profit / (Loss) Before Tax		
Continuing operations	(671.47)	8.51
Discontinued operations	(34.45)	(205.80)
Adjustment for:		
Depreciation and amortisation expense	390.75	357.48
Finance costs (Including of MSME Interest)	381.92	343.56
Foreign exchange loss / (gain) (unrealised)	37.85	(166.24)
Loss on sale/discard of Property, Plant & Equipment	2.46	0.93
Allowance for Doubtful debts and advances (Net)	35.64	(0.76)
Shortfall arising from the settlement of Insurance claim	94.06	-
Net Expenses recognised in respect of equity settled share based payments	22.35	-
Provision for defined benefit plans and compensated absences	4.44	34.27
Interest income	(6.96)	(20.52)
Hyperinflationary effect on Consolidated Statement of Profit and Loss	(0.03)	16.06
Share of (profit)/loss of associate of step down subsidiary	(17.58)	(5.33)
Net gain arising on Financial Liabilities measured at Fair Value Through Profit or Loss (FVTPL)	-	(18.07)
Operating Profit before working capital changes	238.98	344.07
Adjustment for:		
Increase/(Decrease) in Non Financial Liabilities	(7.10)	12.96
Increase/(Decrease) in Financial Liabilities	530.60	352.85
(Increase)/Decrease in Non Financial Assets	6.16	(17.57)
(Increase)/Decrease in Financial Assets	(332.58)	165.06
Cash generated from operations	436.06	857.37
Taxes Paid (Net)	(20.38)	(185.99)
Net Cash Flow from / (used in) Operating activities	415.68	671.39
Cash Flow from Investing Activities		
Purchase of Property, Plant & Equipment and Intangible Assets	(237.60)	(296.56)
Sale/ (Purchase) of non-current investments	-	(34.50)
Dividend received from associate company	9.80	-
Acquisition of additional interest in subsidiary from non-controlling interests	(220.15)	-
Maturity of / (Investment in) Fixed Deposit (Net)	261.89	159.41
Interest Received	6.96	11.46
Net Cash Flows from / (used in) Investing Activities	(179.10)	(160.19)
Cash Flow from Financing Activities		
Proceeds from Issue of Equity Shares under Employee Stock Option Scheme / Plan	0.10	4.53
Proceeds from / (Repayment of) Long Term Borrowings (Net)	(506.12)	537.81
Proceeds from / (Repayment of) Short Term Borrowings (Net)	80.14	(854.36)
Payment of lease liabilities	(83.17)	(77.99)
Interest Paid	(318.11)	(287.53)
Net Cash Flow from / (used in) Financing Activities	(827.16)	(677.54)
Net Increase/ (Decrease) in Cash & Cash Equivalents	(590.58)	(166.34)
Cash & Cash Equivalents at the beginning of the period	1,085.55	1,040.71
Cash & Cash Equivalents at the end of the period	494.97	874.36

Notes:

(a) The above Consolidated Statement of Cash Flows has been prepared under the "Indirect Method" as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.

(b) Cash and Cash Equivalents comprises of :

(Rs.in Million)

Particulars	As at September 30, 2026	As at March 31, 2025
Balances with banks in current accounts	493.66	758.62
Bank deposits with original maturity of less than three months	-	114.74
Cash on hand	1.31	1.00
Cash and cash equivalents in Consolidated Balance Sheet	494.97	874.36

KALYANIWALLA & MISTRY

Place: Mumbai
Date: November 03, 2026

FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar
DIN: 01077379

CAMLIN FINE SCIENCES LIMITED MUMBAI

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

ANNEXURE -1

CAMLIN FINE SCIENCES LIMITED

UNAUDITED CONSOLIDATED SEGMENT INFORMATION FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2026

(Rs. in Million)

PARTICULARS	QUARTER ENDED			PERIOD ENDED		YEAR ENDED
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Segment Revenue						
Specialty Ingredients	4,078.80	4,013.17	3,231.33	8,091.97	6,167.41	13,116.23
Aroma	471.55	774.07	798.54	1,245.62	1,365.41	2,390.86
Performance Chemicals & Others	1,856.82	1,748.90	1,572.51	3,605.72	3,084.15	5,814.88
Gross Segment Revenue	6,407.17	6,536.14	5,602.38	12,943.31	10,616.97	21,321.97
Less: Inter Segment Revenue	1,492.52	1,337.35	1,099.72	2,829.87	2,037.11	4,088.89
Revenue from operations	4,914.65	5,198.79	4,502.65	10,113.44	8,579.86	17,233.08
Segment Results						
Specialty Ingredients	327.91	254.66	358.87	582.57	658.73	1,276.27
Aroma	(108.90)	(33.81)	87.00	(142.70)	66.58	(240.23)
Performance Chemicals & Others	(196.69)	(44.41)	(89.59)	(241.11)	(166.11)	32.75
Segment results before exceptional items	22.33	176.44	356.28	198.76	559.21	1,068.79
Less:						
Exceptional Items						
Specialty Ingredients	19.26	108.80	-	128.06	-	76.34
Aroma	-	-	-	-	-	-
Performance Chemicals & Others	-	-	-	-	-	-
Unallocated	-	-	-	-	-	-
Segment results after Exceptional Items	3.07	67.64	356.28	70.70	559.21	992.45
Less / (Add):						
(i) Finance costs	205.92	140.05	178.48	345.97	327.04	729.40
(ii) Depreciation & Amortisation	199.19	191.56	176.55	390.75	337.88	709.19
(iii) Other income (excluding foreign exchange gain)	(13.63)	(13.40)	(13.94)	(27.03)	(18.77)	(287.92)
(iv) Foreign exchange loss / (gain)	(35.93)	83.69	(28.68)	47.76	(90.12)	-
(v) Exceptional items (unallocated)	(0.00)	2.30	-	2.30	-	178.26
(vi) Share of profit / (loss) of associate	3.61	13.97	(3.58)	17.58	5.33	16.62
Profit / (Loss) before tax	(348.87)	(322.59)	40.29	(671.47)	8.51	(319.86)

PARTICULARS	AS AT					
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Segment Assets						
Specialty Ingredients	11,252.64	12,034.58	7,875.61	11,252.64	7,875.61	11,487.74
Aroma	3,681.70	3,863.87	3,592.17	3,681.70	3,592.17	3,980.19
Performance Chemicals & Others	6,421.72	6,142.10	7,737.12	6,421.72	7,737.12	6,493.61
Unallocated	1,320.58	1,258.95	1,164.35	1,320.58	1,164.35	1,277.49
Total	22,676.64	23,299.50	20,369.25	22,676.64	20,369.25	23,239.03
Segment Liabilities						
Specialty Ingredients	6,941.39	7,362.00	5,940.92	6,941.39	5,940.92	6,886.61
Aroma	2,187.50	2,262.48	2,100.85	2,187.50	2,100.85	2,431.04
Performance Chemicals & Others	4,118.92	3,708.61	3,601.22	4,118.92	3,601.22	3,800.73
Unallocated	9,428.83	9,966.41	8,726.26	9,428.83	8,726.26	10,120.65
Total	22,676.64	23,299.50	20,369.25	22,676.64	20,369.25	23,239.03

Notes:

The Managing Directors review and evaluate the Group's operating performance to make decisions about resources to be allocated to various businesses and have been identified as Chief Operating Decision Makers (CODM).

Based on the information provided to the CODM, it has been determined that the Group has three business reporting segments. The business of each segment comprises of :

1. Specialty Ingredients : This is the main business area of the Group's operation and includes marketing of conventional antioxidant chemicals, and manufacturing and marketing of blends, emulsifiers, functional ingredients, starches, additives, etc. catering to industries engaged in Food, Animal Nutrition & Feed, Pet Food, Bio diesels, Oil & Fat, Dairy, Bakery, Confectionery, Meat, etc. All these products include inorganic, natural as well as clean label.

2. Aroma : This segment of the Group's operation includes manufacturing and marketing of aromatic products such as Methyl Vanillin, Ethyl Vanillin and related derivatives.

3. Performance Chemicals & Others: This segment will include the manufacturing and marketing of chemical such as Diphenols, Phenolic Compounds, Performance & Industrial chemicals and other downstream & derivatives. This segment will also include other minor residuary businesses.

Accordingly, segment information is presented in respect of the above identified business segments, wherein the performance is evaluated based on operational EBITDA (without foreign exchange gain / loss).

All inter-segment transactions are conducted on normal commercial terms not more favourable than those generally available to external parties and in line with the arm's length principle.

Comparative figures for previous financial periods have been recast to reflect the changes in the reporting segments and to ensure comparability with the segment information presented in the current quarter and period.

Registered Office:
Camlin Fine Sciences Limited, Floor 3 to 5, A & C S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361.

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

REVIEW REPORT
To The Board of Directors
Camlin Fine Sciences Limited

1) We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Camlin Fine Sciences Limited** ("the Company") for the quarter and half year ended September 30, 2026, together with the Standalone Unaudited Balance Sheet, Statement of Standalone Unaudited Cash Flows and notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), duly initialled by us for identification. This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors, at their respective meetings held on November 3, 2026, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Kalyaniwalla & Mistry LLP**
Chartered Accountants
Firm Registration No.: 104607W/W100166

Anil A. Kulkarni
Partner
Membership No.: 047576
UDIN: 26047576UYKVAK4092
November 03, 2026, Mumbai

REVIEW REPORT
To The Board of Directors
Camlin Fine Sciences Limited

1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Camlin Fine Sciences Limited** ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of net profit after tax and total comprehensive income of an associate of a step down subsidiary (refer paragraph 3 below) for the quarter and half year ended September 30, 2026 together with the Consolidated Unaudited Balance Sheet, Statements of Consolidated Unaudited Cash Flows and notes thereon ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations"), duly initialled by us for identification. This Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by Parent's Board of Directors, at their respective meetings held on November 3, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, ("the Act"), read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

2) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

3) The Statement includes the results of the following subsidiaries / step down subsidiaries / associate:

Sr. No.	Name of the Entity	Relationship
Incorporated In India		
i.	Chemolutions Chemicals Ltd.	Subsidiary
ii.	AlgalR Nutra Pharms Private Limited	Subsidiary
Incorporated Outside India		
iii.	CFS North America LLC	Wholly owned subsidiary
iv.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
v.	Solentus North America Inc (Struck off w.e.f. May 12, 2026)	Wholly owned subsidiary

KALYANIWALLA & MISTRY LLP

Sr. No.	Name of the Entity	Relationship
vi.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
vii.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
viii.	Nuvel, S.A.C.	Step down subsidiary
ix.	Britec, S.A.	Step down subsidiary
x.	Inovel, S.A.S	Step down subsidiary
xi.	Grinel, S.R.L	Step down subsidiary
xii.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xiii.	CFS Argentina S.A.	Step down subsidiary
xiv.	CFS Chile De SPA	Step down subsidiary
xv.	CFS PP (M) SDN. BHD	Subsidiary
xvi.	Vitafor Invest NV, Belgium	Step down subsidiary
xvii.	Vitafor NV,	Step down subsidiary
xviii.	Addi-Tech NV	Step down subsidiary
xix.	Vitafor China Ltd.	Step down subsidiary
xx.	Vial SARL	Associate of a step-down subsidiary of Vitafor NV.
xxi.	Vinpai S. A.	Subsidiary
xxii.	Based Algae & Plants, France	Step down subsidiary

4) Based on our review conducted and procedures performed as stated in paragraph 2 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 5(A) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5) Other Matters:

A. We did not review the interim financial results of **13** subsidiaries incorporated outside India and **2** subsidiaries in India included in the Statement, whose interim financial results reflect Group's share of total assets (before consolidation adjustments) of Rs. 10,674.03 million as at September 30, 2026 and Group's Share of total revenues (before consolidation adjustments) of Rs. 3,186.76 million and Rs. 6,894.69 million for quarter and for half year ended, respectively, Group's share of total net loss after tax (before consolidation adjustments) of Rs. 47.55 million and Rs 229.74 million for quarter and for half year ended, respectively, and total comprehensive income (before consolidation adjustments) loss of Rs. 108.96 million and Rs. 205.26 million for quarter and for half year ended, respectively, and cash flow (net outflow) (before consolidation adjustments) of Rs. 221.75 million for the half year ended September 30, 2026.

These interim financial results of the subsidiaries as mentioned in this paragraph have been reviewed by other auditors whose reports have been furnished to us and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 2 above.

In respect of the subsidiaries located outside India, the interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial results of these subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian



Accounting Standards "Ind AS"). We have reviewed the conversion adjustments made by the Parent's Management.


B. The Statement includes interim financial results of **6** subsidiaries incorporated outside India which have not been reviewed, whose interim financial results reflect Group's share of total assets (before consolidation adjustments) of Rs. 1,366.72 million as at September 30, 2026 and Group's Share of total revenues (before consolidation adjustments) of Rs. 19.19 million and Rs. 42.01 million for quarter and for half year ended, respectively, Group's share of total net loss after tax (before consolidation adjustments) of Rs. 40.33 million and Rs. 89.21 million for quarter and for half year ended, respectively, and total comprehensive income (before consolidation adjustments) loss of Rs. 127.76 million and Rs 156.57 million for quarter and for half year ended, respectively and cash flow (net outflow) (before consolidation adjustments) of Rs. 126.91 million for the half year ended September 30, 2026.

The Statement also includes the Group's share of net profit after tax (before consolidation adjustments) and total comprehensive income (before consolidation adjustments) of Rs. 3.61 million and Rs. 17.58 million for quarter and for half year ended, respectively, as considered in the consolidated unaudited financial results, in respect of an associate of a step-down subsidiary, located outside India, which have not been reviewed.

These interim financial results have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate of a step-down subsidiary, is based solely on such interim financial results certified by the Management. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matters.

For **Kalyaniwalla & Mistry LLP**
Chartered Accountants
Firm Registration No.: 104607W/W100166



Anil A. Kulkarni
Partner
Membership No.: 047576
UDIN: 25047576BFDBVK8863
November 03, 2026, Mumbai



Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2026

(Rs.in Million, except per share data)

No.	PARTICULARS	STANDALONE						CONSOLIDATED					
		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total Income from Operations	2,445.83	2,224.86	2,440.42	4,670.68	4,354.80	8,379.18	4,914.65	5,198.79	4,502.65	10,113.44	8,579.86	17,233.08
2	Net Profit / (Loss) for the period from continuing operations (before tax and exceptional items)	(311.74)	(186.72)	(38.10)	(498.48)	(201.86)	(378.23)	(329.61)	(211.49)	40.30	(541.11)	8.51	(65.26)
3	Net Profit / (Loss) for the period before tax from continuing operations (after exceptional items)	(311.74)	(186.72)	(38.10)	(498.48)	(201.86)	(540.92)	(348.87)	(322.59)	40.29	(671.47)	8.51	(319.86)
4	Total Net Profit / (Loss) for the period after tax (after exceptional items)	(200.09)	(123.12)	(36.39)	(323.24)	(143.19)	(329.66)	(297.00)	(336.22)	(149.50)	(633.24)	(256.31)	235.43
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)							(278.54)	(317.06)	(143.84)	(595.62)	(243.45)	276.27
6	Total Comprehensive Income for the period	(184.58)	(86.28)	(78.92)	(270.87)	(183.48)	(376.62)	(346.65)	(163.62)	(159.28)	(510.27)	(146.81)	269.80
7	Equity Share Capital	192.10	192.10	187.98	192.10	187.98	192.09	192.10	192.10	187.98	192.10	187.98	192.09
8	Other Equity				8,847.42	8,255.77	9,096.16				9,528.63	8,707.75	10,216.71
9	Earnings per share (of Re 1/ each) (not annualised)												
	-Basic Rs.	(1.04)	(0.64)	(0.19)	(1.68)	(0.76)	(1.74)	(1.45)	(1.65)	(0.77)	(3.10)	(1.30)	1.46
	-Diluted Rs.	(1.04)	(0.64)	(0.19)	(1.68)	(0.76)	(1.74)	(1.45)	(1.65)	(0.77)	(3.10)	(1.30)	1.44

Note: The above information is an extract of the detailed format of unaudited results for the quarter ended September 30, 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter September 30, 2026 are available on the Company's website at www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

For Camlin Fine Sciences Limited

Ashish S. Dandekar
Chairman & Managing Director
DIN: 01077379

CAMLIN FINE SCIENCES LIMITED MUMBAI

Place: Mumbai
Date: November 03, 2026

CFS Camlin Fine Sciences